Phaseline

Targets › CPSF6

CPSF6 (Cleavage and polyadenylation specificity factor subunit 6): drug programs, companies and trials

1 program from 1 company in 27 trials: 17 Phase 2, 7 Phase 3, 2 Phase 4, 1 Phase 1; Infectious disease; next expected readout Mar 2027.

Component of the cleavage factor Im (CFIm) complex that functions as an activator of the pre-mRNA 3'-end cleavage and polyadenylation processing required for the maturation of pre-mRNA into functional mRNAs. CFIm contributes to the recruitment of multiprotein complexes on specific sequences on the pre-mRNA 3'-end, so called cleavage and polyadenylation signals (pA signals). (UniProt, Q16630)

Open in Phaseline: the race on CPSF6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesLenacapavir
Structural capsid protein inhibitor
CA, CPSF6, GAG, PROT, UNKNOWN, CAPSIDPhase 3Pre-Exposure Prophylaxis of HIV Infection; HIV Pre-exposure Prophylaxis; HIV Infections; HIV-1-infection …Mar 2027

Conditions

HIV-1-infection (10) Pre-Exposure Prophylaxis of HIV Infection (7) HIV-1 Infection (3) HIV Pre-exposure Prophylaxis (2) HIV Infections (1) HIV-1-Infection (1) HIV (1) HIV Prevention (1) Human Immunodeficiency Virus (1)

Modalities

mixed (1)

Companies

Gilead Sciences (1)

Related targets

CA (1) GAG (1) PROT (1) UNKNOWN (1) CAPSID (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.